D&D Pharmatech
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5th Floor I&c Building 24 Pangyo-ro 255 ...Phone Number
+82 3180197771Website
www.ddpharmatech.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About D&D Pharmatech
D&D Pharmatech is a clinical-stage global biotech company that funds the development of medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. The company was founded in 2014 and has offices in Korea and US.Explore more
D&D Pharmatech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is D&D Pharmatech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on D&D Pharmatech recently announced quarterly report
Product Launch: Get notified when D&D Pharmatech launches new products
Funding: Get notified immidiatlly once D&D Pharmatech has new funding data
D&D Pharmatech, which may be a good buyer, showed buying intent in Masked Content Topic
Check if D&D Pharmatech has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at D&D Pharmatech
Website visits: Recent activity has been detected on your website
Check out if D&D Pharmatech is spiking on competitors!
Click to see if D&D Pharmatech had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at D&D Pharmatech
Find more new buyers
Company Profile Activity
Activity Insights
D&D Pharmatech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
D&D Pharmatech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about D&D Pharmatech.
D&D Pharmatech financials insights
Gather financial insights about D&D Pharmatech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series B
$137.1M
2021
Series C
$51M
2025
Debt
$10.8M
D&D Pharmatech Tech Stack
A closer look at the technologies used by D&D Pharmatech
Most Recent Scoops
Funding
Funding
Funding
New Hire
Executive Move
New Hire
Funding
Funding
Funding
Funding
D&D Pharmatech News & Media
D&D Pharmatech Announces Completion of Patient Enrollment for a 48-Week Phase 2 Trial Evaluating the Effectiveness of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist, in the Treatment of MASH
GYEONGGI-DO, South Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company focused on the development of disease-modifying drugs, today, announced that patient enrollment has been completed for DD01-DN-2, an ongoing Phase 2 trial designed to evaluate the efficacy and safety of DD01 in overweight/obese subjects with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH). DD01 is a liver-targeted, loNeuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04
KNOXVILLE, Tenn.--(BUSINESS WIRE)--On January 16, 2025, Neuraly Inc. (Neuraly), a wholly owned subsidiary of D&D Pharmatech Inc., and Enigma Biomedical USA, Inc. (Enigma) announced the signing of a research license and commercialization option agreement for PMI04, a PET (Positron Emission Tomography) imaging biomarker of neuroinflammation developed by Neuraly. Under the agreement, Enigma acquires an exclusive research license for PMI04, as well as the option to negotiate commercialization rD&D Pharmatech Announces Initiation of Dosing in a Phase 2 Trial Designed to Evaluate the Efficacy and Safety of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist in Overweight/Obese Subjects with MASLD/MASH
GYEONGGI-DO, South Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company focused on the development of disease-modifying drugs, today announced that dosing has commenced in a Phase 2 trial designed to evaluate the efficacy and safety of DD01 in overweight/obese subjects with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH). DD01 is a long-actiD&D Pharmatech Granted Fast Track Designation from US FDA for DD01 for the Treatment of NASH/MASH
GYEONGGI-DO, South Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on the development of disease-modifying drugs, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of DD01 for the treatment of adults with non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH). FDA Fast Track designation is inte
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding D&D Pharmatech
Sign Up For FreeTo access detailed company insights
D&D Pharmatech is a clinical-stage global biotech company that funds the development of medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. The company was founded in 2014 and has offices in Korea and US.... Read More
